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Abstract
Background: Hyperactive secretion and pathogenic effects of interleukin (IL)-17 and IgA have been detected in
different arthropathies. Recent evidence has revealed that TH17 cytokines regulate mucosal IgA secretion. However,
it is unknown whether and how IL-17 mediates synovial IgA production. Here we aim to investigate the connection
of synovial IL-17 with IgA production in the joint.
In this study we included synovial fluids (SF) from patients with rheumatoid arthritis (RA; n = 66), spondyloarthritis
(SpA; n = 18) and osteoarthritis (OA; n = 36). The levels of IL-17, IL-6, transforming growth factor (TGF)-β1, B-cell-
activating factor of the TNF family (BAFF) and anti-lipopolyssacharide (LPS) immunoglobulin (Ig)A were investigated
by enzyme-linked immunosorbent assay (ELISA). Total IgA was measured by radial immunodiffusion assay. Synovial
fluid-derived mononuclear cells (SFMC) were stimulated with bacterial antigens or SF-conditioned media, and
cytokines and IgA were analyzed in the supernatants.
Results: IL-17, IL-6 and TGF-β1 were increased in SF from both RA and SpA compared with OA patients. Concentration
of IL-17 correlated with the disease activity score (DAS)-28, IL-6 and anti-LPS IgA levels. Bacterial-stimulated SFMCs from
RA and SpA patients secreted higher IL-17 than vehicle-stimulated SFMCs. Conditioned media with SF containing IL-17
induced anti-LPS IgA production by SFMCs which was independent of IL-6 activity. Concentrations of synovial TGF-β1
and BAFF correlated with anti-LPS and total IgA levels, respectively. Blockade of IL-17 decreased the production of
TGF-β1 and anti-LPS IgA by SF-stimulated SFMCs.
Conclusions: This study reports a connection between IL-17 and IgA secretion in the joint. In addition, it demonstrates
that enterobacterial antigens trigger synovial IL-17 production, and that TGF-β1 and BAFF may mediate the effect of
IL-17 on IgA production. This circuit may contribute to the pathogenesis of inflammatory joint diseases.
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Background
Mucosal surfaces serve as a protective barrier against most
pathogens. These surfaces are protected by a first-line
defense mediated by immunoglobulin A (IgA) [1]. More-
over, it is also known that T helper (TH)17 cells are more
abundantly present at the mucosal surface of the intestine,
compared with other T-cell subsets [2]. Accumulating evi-
dence has demonstrated that TH17 cells contribute to in-
testinal homeostasis by regulating intestinal IgA secretion
supporting a link between intestinal T-cell function and
IgA production [3, 4]. Less is known about the potential
role of TH17 cells for IgA induction in the joint, though
chronic activation of TH17 can cause arthropathies [5, 6]
and hyperactive IgA synthesis occurs in many types of in-
flammatory joint diseases [7–10].
In spite of the long-standing assumption that infectious
agents and their products may influence the development
of osteoarticular diseases [11, 12], our understanding of the
intricate connections linking bacterial components with in-
flammatory arthropathies is still limited. Rheumatoid
arthritis (RA), one of the most common autoimmune
osteoarticular diseases, is characterized by synovial inflam-
mation and hyperplasia, autoantibody production, cartilage
and bone destruction and systemic disorders mainly driven
by pro-inflammatory cytokines and matrix-degrading en-
zymes [13]. Infectious agents and their products have been
largely linked with RA although the precise mechanisms
implicated in this complex relationship is not fully under-
stood [11, 12, 14]. Elucidation of the pathogenic mecha-
nisms that perpetuate RA will open the possibility of better
disease management and rational control of immune dys-
regulation [13]. Spondyloarthritis (SpA) is the second most
prevalent form of chronic inflammatory arthritis (preva-
lence 0.5-1.5%) that mainly affects young adults [15]. SpA
has been traditionally subdivided into subtypes including
ankylosing spondylitis (AS), psoriatic arthritis (PsA), react-
ive arthritis (ReA), arthritis/spondylitis associated with in-
flammatory bowel disease (IBD), and undifferentiated SpA
(uSpA) [16]. However, evidence suggests that SpA is a sin-
gle disease with a heterogeneous phenotype [17]. Although
the etiology of SpA remains obscure, it has demonstrated a
strong association with environmental factors including
pathogenic intestinal microbes [18]. However, whether en-
terobacterial antigens trigger synovial IL-17 in RA and SpA
is still uncertain.
It is known that transforming growth factor (TGF)-β1
has a unique role in driving IgA isotype switching [19],
and is also critical for TH17-cell differentiation [20]. It is
also known that IL-6, a major factor for the differentiation
of naïve CD4 T cells into Th17 cells [21], plays a key role
in B-cell proliferation and antibody secretion [22]. How-
ever, there is no evidence indicating that TGF-β1 or IL-6
together with IL-17 have a role for IgA generation in joint.
Ultimately, B- cell-activating factor of the TNF family
(BAFF) has been recognized as a cytokine that induces
IgA class switching by activating B cells [23]. Interestingly,
IL-17 has also been recently shown to synergize with
BAFF to increase the frequency of autoantibodies, and
high BAFF levels have been considered a measurement of
B-cell dysfunction in autoimmune diseases [24].
In the present study, we aimed to examine the role of
IL-17 in IgA production in the joint. We used synovial
fluids (SF) containing different cytokines rather recombin-
ant cytokines in order to recreate the pathophysiologic
microenvironment of the joints during ongoing inflamma-
tory diseases. These findings identify pathways by which




Synovial fluids (SF) were obtained from 66 RA, 18 SpA
and 36 osteoarthritis (OA) patients from San Luis,
Argentina. Since OA is not associated with infections,
these patients were considered a control group. The RA
and SpA patients met the American College of Rheumatol-
ogy (ACR) [25] and the European Spondyloarthopathy
Study Group (ESSG) criteria [26], respectively. Table 1
shows the demographic features of patients. To enroll in
the study, patients in all groups required knee effusion of
SF. Age, sex and disease duration were recorded (Table 1).
Fifty six RA patients were classified as late stage disease ac-
cording to the ACR criteria [25]. Eight patients with early
SpA were categorized as having disease of less than
6 month-duration (Table 1). The 28-joints disease activity
score (DAS28) was used as a measure of disease activity in
RA [27]. The medium DAS28 of the RA patients was 4.64
± 1.6 (range: 2.42–7.1). The 95%, 44.5% and 21.4% of RA,
SpA and OA patients, respectively were positive for C-
reactive protein (CRP). The SpA group included patients
with AS (1), PsA (5), ReA (3), IBD (1) and uSpA (8). The
current medications were recorded and included: nonste-
roidal anti-inflammatory drugs in 39 patients with RA and
10 with SpA; methotrexate in 40 patients with RA and 11









RA 66 12:54 55
(20–74)
8 (3 months-30 years)
85% chronic phase
(>1 year)
SpA 18 14:4 33
(12–59)
4 (2 months-17 years)
55% chronic phase
(>6 months)
OA 36 11:25 61
(42–83)
-
RA rheumatoidarthritis, SpA spondyloarthritis, OA osteoarthritis,
M:F male:female
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with SpA; leflunomide in 16 patients with RA; hydroxy-
chloroquine in 12 patients with RA; sulfasalazine in 6 pa-
tients with RA and 8 with SpA; anti-TNF in 6 patients
with RA and 1 with SpA; prednisone in 24 patients with
RA. Combined medication was used in the majority of the
patients. Ten patients with RA had no treatment at the
moment of study enrolment since SF drainage was re-
quired in their first visit to the rheumatologist.
Ethical aspects
The study was approved by the Ethics Committee of the
National University of Cuyo, Mendoza, Argentina. In-
formed consent was obtained from all patients included in
the study. The principles of Helsinki Declaration 1975/83
were followed.
Synovial fluid preparation
SF was aspirated from knee joints and mixed immediately
with 50 IU/ml heparin. The volumes of aspired fluids were
5–30 ml. SF of RA and SpA patients were classified as in-
flammatory since all of them had more than 2000 cells/
mm3; in contrast, OA patients had non-inflammatory SF
(less than 2000 cells/mm3) [28, 29]. For cytokine and anti-
body analysis, samples were centrifuged at 250 x xg for
10 min and the supernatants were stored at -20 °C.
Cytokine determination by enzyme-linked immunosorbent
assay (ELISA)
IL-17, TGF-β1 and IL-6 were determined in SF using com-
mercial capture ELISA kits (eBioscience, San Diego, CA,
USA), according to the manufacturer’s instructions. The
limits of detection for the above-mentioned assays were
4 pg/ml for IL-17, 2 pg/ml for IL-6 and 8 pg/ml for TGF-
β1. The SF with levels of these cytokines higher than the
limit of detection was considered positive in the frequency
analysis. BAFF was determined by ELISA kit (Antigenic
America, Huntington Station, NY, USA) which was kindly
provided by Dr. Adriana Gruppi (National University of
Córdoba, Argentina).
Enterobacterial antigen preparations
Yersinia enterocolitica O:8, strain WA-314 (kindly pro-
vided by Dr Kapperud, Department of Bacteriology, Oslo,
Norway) was used for heat killed Yersinia (HKY) prepar-
ation, which consisted in a twice autoclaved bacterial sus-
pension (1 × 1010 bacteria/ml). The absence of bacterial
growth in HKY was tested by plating on Mueller-Hinton
agar and incubation at 26 °C for 48 h. Lipopolysaccharide
(LPS) was obtained as previously described [30].
Synovial anti-enterobacterial IgA and total IgA
Multiwell plates were coated with 100 μl per well of
10 μg/ml LPS in 0.15 M phosphate-buffered saline (PBS)
pH 7.2 at 4 °C overnight. After incubation with 1:50
diluted SF, bound antibodies were demonstrated by reac-
tion with goat anti-human IgA and peroxidase-conjugated
rabbit anti-goat IgG (Sigma, St. Louis, MO, USA) followed
by the addition of the enzyme substrate (H2O2) and
chromogen O-phenylendiamine (Sigma). Optical density
(OD) was measured at 490 nm in an ELISA reader (Bio-
Rad, Hercules, CA, USA). Total IgA levels in SF were de-
termined by radial immunodiffusion assay (Diffu-Plate kit,
Biocientífica, Buenos Aires, Argentina)
Assessment of IL-17, TGF-β1 and anti-LPS IgA in stimulated
mononuclear cells from SF
SF mononuclear cells (SFMC) were obtained using Ficoll-
Hypaque (Histopaque 1077, Sigma). Cells (2 × 106 cells/
well) were cultured in RPMI 1640 medium (Hyclone, Lo-
gan, UT, USA) with 10% fetal bovine serum (FBS) (Sigma),
and stimulated with 107 or 108 bacteria/ml of HKY and in-
cubated at 37 °C in 5% CO2. Supernatants were collected
after 72 h for determination of IL-17 using a commercial
ELISA kit (eBioscience). In addition, SFMC were incu-
bated for 96 h with media conditioned with different dilu-
tions of SF containing IL-17; then, TGF-β1 or anti-LPS
IgA were measured by ELISA. To analyze the role of IL-6
in this effect, cells were incubated in vitro with pharmaco-
logically relevant concentrations of the anti-IL-6 receptor
antagonist tocilizumab (TCZ) (200 μg/ml, Roche Pharma,
Grenzach-Wyhlen, Germany) [31]. To analyze the effect
of synovial IL-17, the cells were stimulated with SF in
presence of the anti-IL-17 (100 μg/ml, Secukinumab,
Novartis Argentina SA, Buenos Aires, Argentina).
Statistical analysis
Differences in the amounts of cytokines or IgA in RA,
SpA and OA patients were compared by using one-way
analysis of variance (ANOVA) followed by Tukey’s mul-
tiple comparison test. Two variables were compared by
unpaired Student´s t test. Differences in the frequencies
of SF with detectable level of cytokine (positive SF) in
each group of patients were analyzed by Fisher´s exact
test. Correlations between two variables were examined
by Spearman’s analysis. A P value less than 0.05 was
considered as statistically significant. All analyses were
performed using GraphPad Prism 5 software (GraphPad
Software, San Diego, CA, USA).
Results
Synovial IL-17, IL-6 and TGF-β1 production in patients
with RA and SpA
Since IL-17 has been associated with the pathogenesis of
RA and SpA [32, 33], we first studied this cytokine in SF
from RA and SpA in comparison with OA patients. Next,
we analyzed the cytokines TGF-β1 and IL-6 that in com-
bination are required for TH17 development [21]. The fre-
quency of SF with detectable levels of each cytokine was
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also compared. We found a higher number of patients
with detectable synovial IL-17 in RA and SpA compared
to OA (62% and 59%, respectively versus 5.5%) (P < 0.0001
compared with OA for both comparisons). Of note, the
IL-17 median concentration was significantly higher in SF
from RA or SpA compared to OA patients (P < 0.0001)
(Fig. 1a). We next examined whether an association exists
between the levels of IL-17 and disease activity in RA. We
found that synovial production of IL-17 correlated with
RA disease activity as measured by DAS28 (r = 0.4, P <
0.05) (Fig. 1b). The determination of TGF-β1 revealed
similar differences as those observed for IL-17 as higher
percentage of RA or SpA patients had detectable levels of
TGF-β1 in their SF (P < 0.0001 compared with OA for
both comparisons) and the median values of this cytokine
were higher in SF from both RA and SpA patients (P <
0.0001 RA vs OA, and P < 0.01 SpA vs OA) (Fig. 1c). Fur-
thermore, a high percentage of RA, SpA and OA patients
had IL-6 in their SF (98%, 93% and 90%, respectively),
while the median concentration of this cytokine was sig-
nificantly elevated in RA and SpA patients compared with
OA patients (P < 0.0001 for both comparisons) (Fig. 1d).
Remarkably, when we analyzed the relationships between
the different cytokines, we observed a positive correlation
between IL-6 and IL-17 in SF from RA and SpA patients
(r = 0.3; P < 0.01) (Fig. 1e).
Secretion of IL-17 by SFMCs from patients with RA and
SpA after stimulation with enterobacterial antigens and
anti-enterobacterial IgA response
We investigated a possible causative link between bac-
terial antigens and synovial IL-17 production. Therefore,
we evaluated the effects of stimulating with HKY in
SFMC obtained from RA and SpA patients. We found
that SFMC from RA and SpA patients secreted signifi-
cantly higher amounts of IL-17 following stimulation,
and this effect was found to be dose-dependent when
different HKY concentrations were used (Fig. 2a). Con-
sistent with our previous findings demonstrating a cor-
relation between IL-17 and IL-6, we found that IL-6 was
also induced by HKY-stimulation of SFMC (Fig. 2b). In
presence of TCZ, an inhibitor of IL-6 function, although
IL-6 was secreted (Fig. 2b), IL-17 production by HKY-
stimulated SFMC significantly decreased (Fig. 2c). These
Fig. 1 Levels of IL-17, IL-6 and TGF-β1 in synovial fluids from patients with arthritis. Concentrations of cytokines and frequencies of patients with detectable
concentrations of IL-17 (a), TGF-β1 (c), and IL-6 (d) in synovial fluids (SF) of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis
(OA). Bars show the mean. **P< 0.01, ***P< 0.0001compared with OA. b Correlation between the IL-17 concentration and DAS28 in SF from patients with
RA. e Correlation between the concentrations of IL-6 and IL-17 in SF of RA and SpA patients. The correlations were assessed by the Spearman’s
rank correlation
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results suggest that IL-6 mediated IL-17 secretion by en-
terobacterial antigen in SFMC. To study the influence of
IL-17 on the induction of IgA in the joint, we next ana-
lyzed anti-LPS IgA in supernatants of SFMC stimulated
with media conditioned with different dilutions of SF
with high IL-17 and IL-6 concentrations. We found a
dose-dependent induction of anti-LPS IgA by IL-17
which could not be inhibited by TCZ (Fig. 2d). Our data
suggest that production of IgA specific to enterobacterial
antigens is associated with IL-17 levels and that IL-6 is
not essential for IL-17-induced IgA responses.
Interaction of IL-17, TGF-β1 and BAFF in synovial IgA
production
Since SF recapitulates the microenvironment of joints,
we measured anti-enterobacterial IgA in the SF from the
patients to correlate the levels of this immunoglobulin
with IL-17 concentration. Our results revealed a signifi-
cant correlation between IL-17 production and anti-LPS
IgA antibodies in SF from RA and SpA patients (r = 0.5;
P < 0.01) (Fig. 3a). This correlation raised the possibility
that IL-17 may contribute to LPS-specific IgA responses.
TGF-β1 has been shown to have a direct role on class
switching to IgA [19, 34, 35], and we also demonstrated
a positive correlation between LPS-specific IgA response
and TGF-β1 levels in SF from RA and SpA patients (r =
0.5; P < 0.05) (Fig. 3b). Therefore, we explored a possible
indirect mechanism by which IL-17 could influence IgA
production through TGF-β1. We detected TGF-β1 in-
duction in SFMCs stimulated with medium conditioned
with different SF containing IL-17 (20 pg/ml) and
undectable TGF-β1 levels (Fig. 3c). Finally, we found that
SF with detectable levels of IL-17 and TGF-β1 had sig-
nificantly higher levels of total IgA compared with those
with undetectable levels of both cytokines (Fig. 3d). Re-
markable, SF containing TGF-β1 and lacking IL-17 had
very low concentration of IgA. However, SF containing
IL-17 but lacking TGF-β1 showed high concentrations of
IgA (Fig. 3d). In addition, we analyzed BAFF as this
cytokine has been associated with IL-17 in antibody re-
sponses [24]. As expected, we observed correlation be-
tween BAFF and IgA concentrations in the SF from
patients (Fig. 4a). Interestingly, we found significantly
higher BAFF levels in SF that were IL-17-positive but
Fig. 2 Association between IL-17 production and IgA anti-enterobacterial antigens. a Dose-dependent IL-17 production in culture supernatants of SF
mononuclear cells (SFMC) (2 × 106 cells/well) after 72 h stimulation with 107 or 108 bacteria/ml of heat-killed Yersinia (HKY). Concentrations of IL-6 (b) and
IL-17 (c) in culture supernatants of SFMC (2 × 106 cells/well) following 72 h stimulation with 108 HKY with or without tocilizumab (TZC). d Anti-LPS IgA in
culture supernatants of SFMC (2 × 106 cells/well) following 96 h of stimulation with media conditioned with SF containing different concentrations of IL-17
and IL-6 with or without tocilizumab (TZC). Data are expressed as mean ± SD. *P< 0.05, **P< 0.01
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TGF-β1-negative
- (Fig. 4b). In addition, anti-IL-17 de-
creased TGF-β1 (Fig. 5a) and anti-LPS IgA (Fig. 5b) in
the supernatants of SFMC stimulated with SF, support-
ing the role of IL-17 contained in the SF on the produc-
tion of TGF-β1 and anti-LPS IgA by IL-17 sensitive cells
in SFCM. In summary, these data suggest that in the
joint microenvironment IL-17 functions to induce syn-
ovial IgA in association with TGF-β1 and BAFF.
Discussion
The role of IL-17 in the induction of IgA in the joint is
poorly understood. Most of the available information on
the association between Th17 and IgA comes from stud-
ies of intestinal immunity. In this regard, recent studies
have demonstrated that TH17 cells are the T helper sub-
set responsible for promoting the B cell switch toward
the production of high-affinity T cell-dependent IgA re-
sponses [36]. Moreover, microbial-specific Th17 cells
contribute to intestinal homeostasis by regulating intes-
tinal pIgR expression and IgA secretion [4]. In the
present work we focused on IL-17-mediated induction
of IgA production in the joint.
First, we detected elevated IL-17 concentrations in SF
from both RA and SpA patients compared with control
OA patients. These observations are in accordance with
previous studies in RA and in SpA [6, 32, 33] patients. Fur-
thermore, differences in SF concentrations of IL-6 and
TGF-β1 were similar to those found for IL-17, and positive
a b
c d
Fig. 3 Interaction of IL-17 and TGF-β1 for synovial IgA production. Correlation of IL-17 (a) or TGF-β1 (b) levels with anti-LPS IgA response in SF
from patients with RA and SpA (Spearman’s rank correlation). c TGF-β1 production in culture supernatants of SF mononuclear cells (SFMCs) (2 ×
106 cells/well) following 96 h of stimulation with medium conditioned with different SF containing IL-17 (20 pg/ml). d Total IgA concentrations in
SF with IL-17 and TGF-β1 in detectable (+) or undetectable (-) levels. Bars show the mean.*P < 0.05
a b
Fig. 4 IL-17 and BAFF association for synovial IgA production. a Correlation between BAFF and total IgA concentrations in synovial fluids (SF)
from the patients (Spearman’s rank correlation). b BAFF concentrations in SF with IL-17 and TGF-β1 in detectable (+) or undetectable (-) levels.
Bars show the mean.**P < 0.01
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correlation was also observed between SF concentrations of
IL-17 and IL-6. These results are consistent with the role of
IL-6 and TGF-β1 in the differentiation of IL-17-producing
CD4+ T cells [20, 21, 37] and support the involvement of
IL-17 in the pathogenesis of the inflammatory arthritis (RA
and SpA) but not in OA. Noteworthy, we detected a posi-
tive association between IL-17 and disease activity evalu-
ated by DAS28 in RA. In accordance, in other study, Th17
cells positively correlated with both CRP levels and DAS28
in RA patients [6]. Although this correlation was more diffi-
cult to assess in SpA, accumulating evidence firmly impli-
cates IL-17 in the pathogenesis of SpA [33, 38].
In spite of considerable progress in the elucidation of
the relationship between bacterial infection and rheuma-
tologic disorders [11, 12, 14], the precise mechanism by
which bacterial enteroantigens modulate the local in-
flammatory microenvironment and influence clinical
course of inflammatory arthropathies are poorly under-
stood. Here, we found that stimulation with Yersinia
antigens promotes robust IL-17 production by SFMC of
RA and SpA patients. This induction was IL-6-
dependent in line with the well-established role of IL-6
as a potent inducer of TH17 differentiation [21, 37], and
the major role of IL-6 in the pathophysiology of arthritis
[39]. Additionally, we demonstrated an IL-17-IgA link in
the joint since SFMC secreted anti-LPS IgA in response
to stimulation with medium conditioned with SF con-
taining different IL-17 concentrations (Fig. 2d). In line
with this finding, a relationship between TH17 and B-
cell differentiation has been identified [40]. In addition,
it has been recently reported that lung IgA response is
dependent on TH17 cells since depletion of IL-17 ablates
IgA responses in the lung [41]. Moreover, IL-17 has been
involved simultaneously in both aggravating intestinal
inflammation and promoting the development of rapidly
progressive IgA nephropathy in patients with Crohn’s
disease [42]. These findings demonstrate a connection
between bacterial stimulation, IL-17 and promotion of
local IgA response in arthropathies. We found that IL-6
was not essential for IL-17 effects. In line, IL-6 was not
required for IgA+ B cell development or specific mucosal
IgA responses in other in vivo systems [43, 44].
We demonstrated that SF with elevated IL-17 and
TGF-β1 levels had higher anti-LPS IgA levels reinforcing
TH17-IgA connection in arthritis. TGF-β1 is a direct
regulator of class switching to IgA [19, 45, 46]. There-
fore, to investigate whether IL-17 works indirectly for
helping the synovial IgA response, we analyzed the rela-
tionship between IL-17 and TGF-β1. Our data indicated
that medium conditioned with SF containing IL-17 in-
duced TGF-β1 production by SFMC. Accordingly, the SF
with both cytokines showed the higher levels of IgA in
SF. Interestingly, SF containing TGF-β1 but lacking IL-
17 showed low IgA concentration suggesting that IL-17
or TH17 cytokines may play an essential role for synovial
IgA generation. A recent report further demonstrated
that TH17 cells may convert into T follicular helper
(TFH) cells in Peyer’s patches and induce intestinal IgA
[3]. It has been shown that IL-21 can modulate B cell
differentiation by enhancing TGF-β1-driven IgA produc-
tion [46]. Moreover, Cao et al have recently demon-
strated that IL-21, produced by both TH17 and TFH
cells, can augment IgA responses mediated by TGF-β1
and retinoic acid in the intestine, and intestinal sources
of IL-21 directly induce IgA production [47]. Therefore,
the role of IL-21 in IgA generation in the joint will re-
quire further investigation. However, it has been also
demonstrated that TH17 cell cytokines, IL-17 and IL-21
are able to function indirectly to induce IgA production
by promoting the expression of BAFF [47]. In line, our
data showed that SF with detectable levels of IL-17 but
lacking TGF-β1 had elevated levels of IgA (Fig. 3d) and
BAFF (Fig. 4b). These results indicate alternative promo-
tion of TGF-β1 and BAFF by IL-17 for synovial IgA gen-
eration. Moreover, blockade of IL-17 functions using a
specific monoclonal antibody reduced the induction of
TGF-β1 and anti-LPS IgA in SF-stimulated SFMCs. We
assume that these findings support again the IL-17 ef-
fects on the induction of synovial TGF-β1 and IgA. Re-
markably, IgA concentration has been related with
Fig. 5 Blockade of IL-17 decreases the induction of TGF-β1 and anti-LPS IgA in SF-stimulated SFMCs. TGF-β1 (a) and anti-LPS IgA (b) in supernatants of
SF mononuclear cells (SFMCs) (2 × 106 cells/well) following stimulation with media conditioned with synovial fluid (SF) containing IL-17 in presence of
anti-IL-17.*P < 0.05. Bars show the mean
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active arthritis [9, 10], and in the last decade it has be-
come clear that IgA is a very potent stimulus to initiate
pro-inflammatory cellular processes [48]. Our study
demonstrates the association between IL-17 and IgA
responses in the microenvironment of the joint.
Conclusions
Taken together, our results revealed that combined secre-
tion of IL-17, IL-6 and TGF-β1 is a hallmark of inflamma-
tory arthropathies. Moreover, our findings sustain the
notion that synovial IL-17 is sensitive to bacterial enteroan-
tigens derived from intestinal infections. These data sup-
port an association between IL-17 and IgA responses in the
joint, and the involvement of TGF-β1 and BAFF in the
mechanisms of IgA-induction by IL-17.
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